Mimi L. Quan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mimi L. Quan has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Joseph M. Luettgen
Research and Development , Bristol-Myers Squibb Company , P.O. Box 5400, Princeton , New Jersey 08543 , United States
7 shared publicationsRuth R. Wexler
Research and Development , Bristol-Myers Squibb Company , P.O. Box 5400, Princeton , New Jersey 08543 , United States
7 shared publicationsKaren A. Rossi
Research and Development , Bristol-Myers Squibb Company , P.O. Box 5400, Princeton , New Jersey 08543 , United States
6 shared publicationsRobert M. Knabb
Research and Development, Bristol-Myers Squibb, PO Box 5400, Princeton, NJ 08543-5400, United States
5 shared publications- Christopher D. Ellis
Bristol-Myers Squibb Co., PO Box 80500, Wilmington, DE 19880-0500, USA
4 shared publications Pancras C. Wong
Discovery Chemistry and Cardiovascular Biology, Research and Development, Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08543, United States
4 shared publications
Latest Publications
- 18 May 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (17) , 7425-7447
Factor XIa Inhibitors as New Anticoagulants
With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved. Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.
- 18 May 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (17) , 7425-7447
Factor XIa Inhibitors as New Anticoagulants
With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved. Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.
- 1 September 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (17) , 4056-4060
Macrocyclic factor XIa inhibitors
- 1 September 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (17) , 4056-4060
Macrocyclic factor XIa inhibitors
- 17 January 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (3) , 955-969
Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors
Antithrombotic agents that are inhibitors of factor XIa (FXIa) have the potential to demonstrate robust efficacy with a low bleeding risk profile. Herein, we describe a series of tetrahydroquinoline (THQ) derivatives as FXIa inhibitors. Compound 1 was identified as a potent and selective tool compound for proof of concept studies. It exhibited excellent antithrombotic efficacy in rabbit thrombosis models and did not prolong bleeding times. This demonstrates proof of concept for the FXIa mechanism in animal models with a reversible, small molecule inhibitor.
- 17 January 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (3) , 955-969
Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors
Antithrombotic agents that are inhibitors of factor XIa (FXIa) have the potential to demonstrate robust efficacy with a low bleeding risk profile. Herein, we describe a series of tetrahydroquinoline (THQ) derivatives as FXIa inhibitors. Compound 1 was identified as a potent and selective tool compound for proof of concept studies. It exhibited excellent antithrombotic efficacy in rabbit thrombosis models and did not prolong bleeding times. This demonstrates proof of concept for the FXIa mechanism in animal models with a reversible, small molecule inhibitor.
- 1 February 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (4) , 1373-1377
Phenyltriazolinones as potent factor Xa inhibitors
- 1 February 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (4) , 1373-1377
Phenyltriazolinones as potent factor Xa inhibitors
- 1 November 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (21) , 5584-5589
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
- 1 November 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (21) , 5584-5589
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
- 1 April 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (7) , 1795-1798
Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
- 1 April 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (7) , 1795-1798
Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
- 16 July 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (6) , 1729-1744
Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3‘-aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).
- 16 July 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (6) , 1729-1744
Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3‘-aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).
- 1 July 2004
- Vol. 7 (4) , 460-9
The race to an orally active Factor Xa inhibitor: recent advances.
Factor Xa (fXa) is a key enzyme in the coagulation cascade and an essential component of the prothrombinase complex, which activates prothrombin to thrombin, leading to fibrin clot formation. In the search for a more effective and safer orally active anticoagulant, fXa has emerged as a major target for potential therapeutic applications in the treatment and prevention of thrombosis. This review focuses on recent advances in the chemistry of drug design and lead optimization of orally bioavailable fXa inhibitors. Many of these orally active fXa inhibitors are currently in clinical trials and are anticipated to change the landscape of thrombosis therapy.
- 1 July 2004
- Vol. 7 (4) , 460-9
The race to an orally active Factor Xa inhibitor: recent advances.
Factor Xa (fXa) is a key enzyme in the coagulation cascade and an essential component of the prothrombinase complex, which activates prothrombin to thrombin, leading to fibrin clot formation. In the search for a more effective and safer orally active anticoagulant, fXa has emerged as a major target for potential therapeutic applications in the treatment and prevention of thrombosis. This review focuses on recent advances in the chemistry of drug design and lead optimization of orally bioavailable fXa inhibitors. Many of these orally active fXa inhibitors are currently in clinical trials and are anticipated to change the landscape of thrombosis therapy.
- 25 February 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (6) , 1023-1028
Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors
- 25 February 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (6) , 1023-1028
Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors
- 24 December 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (3) , 369-373
Nonbenzamidine tetrazole derivatives as factor Xa inhibitors
- 24 December 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (3) , 369-373
Nonbenzamidine tetrazole derivatives as factor Xa inhibitors